Biotech Bros

This week on the podcast Agustin sits down with the Lynn Kirkpatrick the CEO of Ensysce Biosciences. Ensysce is an innovative company that is seeking to address the opioid crisis by leveraging advanced chemistry to prevent opioid abuse and ensure targeted and appropriate dosing of pain medications. Apart from opioids, Ensysce is looking to leverage their technology across a host of indications with the goal of making  drug delivery safer and more effective.  If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin discusses some new developments in the Alzheimer's space with the FDA's recent CRL for Eli Lilly's beta amyloid antibody. He also shares his thoughts on Leap Therapeutics' acquisition of Flame Biosciences and what it means for future commercialization strategies  Dive deep into the motivations and mechanics behind some very successful people. Risk takers, dreamers, business folk and believers discuss the journey toward their goals. Listen on: Apple Podcasts   Spotify If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin discusses the excitement for 2023 in biotech investing and highlights some key tailwinds that could provide a return to positive returns for investors. He also discusses the rather lackluster JPM conference and highlights the troubles plaguing Fate Therapeutics and other natural killer cell therapy companies.  If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin sits down with the Samina Bari. Samina is a biotech executive & strategic advisor, where she drives the development of strategies and compelling corporate narratives that influence investor, media, peer and public perception.  On this podcast we discuss a host of topics from Samina's journey, to understanding the importance of value perceptions in biotech, to creating corporate presentations, and identifying red flags early prior to investing in companies. If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin discusses Madrigal Pharmaceuticals' recent phase III win in NASH, he highlights another monoclonal antibody in the Alzheimer's space, and provides a reflection on the markets in 2022.  If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin shares some recent action and news in the biotech market from failed acquisitions to a pending purchase to questions around a synthetic biology powerhouse. If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin provides updates on key readouts from Affimed and Leap Therapeutics in particular setting the record straight for their recent data readouts. In addition he shares some exciting news regarding a new initiative! If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin talks about the recent fluctuations within the market, the 300 million dollar IPO of a big time base editing gene therapy company, and highlights an interesting play within the NASH space.  The Foundation of Daily Health, AG1 by Athletic Greens Unlock Your Free One Year Supply of Vitamin D3+K2 and 5 free Travel Packs If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin sits down with the Bryan Kobel CEO of TC Biopharm. Bryan spent years leading healthcare investment banking at EF Hutton and the Alberleen Group before switching roles and joining TC Biopharm.  On this podcast we discuss a host of topics from TC Biopharm's IPO earlier in the year, to the state of biotech and equity markets, to the transformative technology behind TC Biopharm.   Foresight: The CPA Podcast Hear about how sustainability is integrating into the business world. Listen on: Apple Podcasts   Spotify If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin talks recent macroeconomic trends and their implications on the stock market and biotech specifically, highlights the positive phase 3 data for another Biogen Alzheimer's drug, and shares the recent approval for Amylyx Pharmaceuticals and their 6-figure a year drug for ALS.  If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin discusses news around Amgen's big 1L data drop for its KRAS inhibitor Lumakras, the shifting perceptions for $AMLX and what could become an approval for their ALS therapy, and the shortsightedness of the FDA and CDC around approving covid boosters based only on mouse data! If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin highlights the recent data update from this small biotech company. The company is up already 119% in the past month and their most recent data may convince big pharma that an acquisition is warranted. Additionally, he discusses the one biotech company that the whole street should love: Leap Therapeutics If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin addresses the flurry of acquisitions that have precipitated in the recent weeks as well as the growing excitement in the sector as indices rebound from their May lows. He also highlights the recent data from Alnylam Pharmaceuticals regarding their therapy for ATTR-CM and the increasingly competitive market that is developing. If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin discusses Leap Therapeutics and their R&D day as well as the news that Novartis is discontinuing their PD-L1 submission for NSCLC and finally he sheds light on a scandal that is rocking neuroscience research and Alzheimer's drug development. If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin discusses the recent acquisition activity in the biotech space, some positive news for Amylyx Pharmaceuticals regarding a new chance to convince regulators of an approval at their second ad-board, and an incredible data readout for a new gene therapy targeting Huntington's Disease.  If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin discusses the recent data release from CRISPR Therapeutics, Galapagos' CAR-T cell therapy acquisition, and the over-saturation of SCD therapies entering the market.  If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin sits down with Maxim Jacobs. Maxim is a senior vice president at Russo Partners and has multiple years of experience in biotech investing. On this episode, Agustin and Maxim discuss the recent biotech market fluctuations and sell-off as well as some practical advice for retail investors looking to enter the space. If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

On this week's episode, Agustin discusses the recent data release of Jemperli and how it may be a viable solution for dMMR solid tumor patients. He also provides updates on Amylyx Pharmaceuticals and their recent approval in Canada, Leap Therapeutics and their prostate cancer readout, and Infinity Pharmaceuticals and their risky jam-packed future.  If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

On this week's episode, Agustin discusses the failures of targeting TIGIT antibodies, the competitive race for KRAS superiority, and the pitfalls of Caribou Biosciences and their allogeneic CAR-T cell therapy.  If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

On this week's episode, Agustin shares some preliminary insights from ASCO and dives into both the lack of data from $AFMD and the less than spectacular update from $PDSB. Additionally, yet another biotech company has been acquired and this one is a late stage commercial company! Is there hope for $XBI after all? If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com